Spero therapeutics investor relations
WebApr 14, 2024 · Investor Relations Contact: Ted Jenkins Vice President, Investor Relations and Strategic Finance [email protected] (617) 798-4039 Media Inquiries: Lora Grassilli, Health Media Relations Zeno Group [email protected] 646 … Web1 day ago · Investor Relations Contact: Ted Jenkins Vice President, Investor Relations and Strategic Finance [email protected] (617) 798-4039. Media Inquiries: Lora Grassilli, Health Media Relations ...
Spero therapeutics investor relations
Did you know?
WebJun 30, 2024 · These forward-looking statements should not be relied upon as representing Spero’s views as of any date subsequent to the date of this press release. Investor Relations Contact: Ashley Robinson LifeSci Advisors [email protected] 617-430-7577 Media Contact: [email protected] Source: Spero Therapeutics, Inc. Share WebMay 17, 2024 · EPS of -$1.01 misses by $0.06 Revenue of $2.07M (-71.66% Y/Y) beats by $144.00K Spero Therapeutics, Inc. ( NASDAQ: SPRO) Q1 2024 Earnings Conference Call May 16, 2024 4:30 PM ET Company...
Web1 day ago · Spero Therapeutics, headquartered in Cambridge, Massachusetts, is a multi-asset, clinical-stage biopharmaceutical company focused on identifying, developing, and … Web1 day ago · Investor Relations Contact: Ted Jenkins Vice President, Investor Relations and Strategic Finance [email protected] (617) 798-4039 Media Inquiries: Lora …
WebSpero Therapeutics is pursuing collaborations with partners for expertise and funding support. Partner with Us Investor Relations Stock information, SEC filings, corporate … Web1 day ago · Spero Therapeutics also has an IV-administered next generation polymyxin product candidate, SPR206, developed from its potentiator platform, which is in …
WebMar 13, 2024 · Investor Relations Contact: Ted Jenkins Vice President, Investor Relations and Strategic Finance [email protected] (617) 798-4039 Media Inquiries: Lora Grassilli, Health Media Relations Zeno Group [email protected] 646-932-3735 Tired of arriving late to the Big Returns Party?
WebApr 14, 2024 · Spero Therapeutics, Inc. today announced two poster presentations at the 33rd European Congress of Clinical Microbiology and Infectious Diseases (ECCMID) being … discovery kids sharks bookWebApr 14, 2024 · Investor Relations Contact: Ted Jenkins Vice President, Investor Relations and Strategic Finance [email protected] (617) 798-4039 Media Inquiries: Lora … discovery kids starlight lanternWebSep 7, 2024 · CAMBRIDGE, Mass., Sept. 07, 2024 (GLOBE NEWSWIRE) -- Spero Therapeutics, Inc. (Nasdaq: SPRO), a multi-asset clinical-stage biopharmaceutical company focused on identifying, developing and... discovery kids soundtrackWebApr 6, 2024 · You can find information on the replay and further information related to today's announcement on the Spero Therapeutics website at www.sperotherapeutics.com. At this time, I would like to turn... discovery kids solar vehicle construction setWeb1 day ago · Spero Therapeutics also has an IV-administered next generation polymyxin product candidate, SPR206, developed from its potentiator platform, which is in development to treat MDR Gram-negative infections in the hospital setting. ... Investor Relations Contact: Ted Jenkins Vice President, Investor Relations and Strategic Finance … discovery kids spaceship laser tagWebSpero Therapeutics is a multi-asset, clinical-stage biopharmaceutical company focused on identifying, developing, and commercializing novel treatments for bacterial infections, … discovery kids star planetarium projectorWebApr 14, 2024 · These forward-looking statements should not be relied upon as representing Spero's views as of any date subsequent to the date of this press release. Investor Relations Contact: Ted Jenkins Vice President, Investor Relations and Strategic Finance [email protected] (617) 798-4039. Media Inquiries: Lora Grassilli, Health Media … discovery kids store online